UNSPSC 51182051: Metenolone enantate

This classification denotes an anabolic agent with the molecular formula C27H42O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0SPD480WFH, chemically known as androst-1-en-3-one, 1-methyl-17-((1-oxoheptyl)oxy)-, (5.alpha.,17.beta.)-, but more generally known as metenolone enantate, which bears US NIH Compound Identifier 4089. European Medicines Agency schedules metenolone enantate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG.

Most nations, for tariff purposes, schedule metenolone enantate under HS 29372900. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C(=CC(=O)C4)C)C)C.

UNSPSC 51182051 Metenolone enantate, a Commodity code, covers pharmaceutical manufacturing and supply agreements for branded and generic injectable steroids and hormone therapies distributed through state and local government health systems and correctional facilities. State and local procurement under this code involves manufacturers supplying products through multi-state cooperative purchasing alliances and direct contracts with state departments of health, departments of corrections, and regional public health authorities that manage formulary procurement for institutional pharmacy networks. The actual work being solicited centers on establishing pricing agreements, maintaining cGMP and FDA compliance, ensuring Drug Supply Chain Security Act (DSCSA) compliance, managing relationships with authorized drug wholesalers, and delivering products with specified shelf-life and expiration requirements to meet institutional patient care and medication management protocols.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products for participating state and local government facilities including Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded agreements effective July 1, 2026 for a two-year term with optional extensions. Evaluation emphasizes price competitiveness (75 percent weight), fixed pricing and administrative compliance (10 percent combined), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and accept performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.